Skip to main content
Signal8

LB PHARMACEUTICALS INC (LBRX)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

LB Pharmaceuticals Inc Common Stock logo

LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRXHealthcare
Pre+0.71%$42.31
Close$42.01+10.29%AH$42.50-0.45%since
Mkt Cap$1.36B
Float24.22M
O/S32.36M
Inst Own93.1%
SI23.0%
Dilution
LB Pharmaceuticals Inc Common Stock logoNASDAQ:LBRXPre$42.31+0.71%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202638.5342.2938.0442.01480,310
Nov 5, 202641.0141.0137.9838.09354,371
Nov 4, 202641.4042.0038.7540.85365,764
Nov 3, 202639.6541.4039.1540.33245,838
Nov 2, 202640.5640.9138.2439.04466,448
Oct 30, 202640.1041.2439.1339.70429,474
Oct 29, 202639.8040.7639.2340.15400,679
Oct 28, 202639.5340.3838.4939.83201,737
Oct 27, 202639.1440.3438.5839.64236,346
Oct 26, 202639.0741.0538.4539.34275,975
Oct 23, 202639.2539.7338.2638.73188,570
Oct 22, 202639.1241.5838.3939.42230,854
Oct 21, 202641.1041.2439.0439.23247,157
Oct 20, 202638.8841.4238.2441.00388,486
Oct 19, 202636.9140.1036.0338.81588,523
Oct 16, 202636.6237.3736.0636.74724,805
Oct 15, 202634.5437.4334.5036.69976,646
Oct 14, 202634.1035.5133.8834.00362,715
Oct 13, 202636.1036.1034.4434.79296,791
Oct 12, 202637.2637.4334.5435.93491,509
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$54.00+28.5%
Low $53High $60
Ratings Distribution
BUY
3
HOLD
0
SELL
0
TOTAL3
Insider Trades
InsiderTypeShares
Miller Joseph M profile photoMiller Joseph MGrant/Award200.0K
Kozauer Susan Gani profile photoKozauer Susan GaniGrant/Award200.0K
Deep Track Biotechnology Master Fund, Ltd. profile photoDeep Track Biotechnology Master Fund, Ltd.Purchase286.2K
Nussbaum Ran profile photoNussbaum RanGrant/Award10.0K
RUFFOLO ROBERT R profile photoRUFFOLO ROBERT RGrant/Award10.0K
Luse Rebecca profile photoLuse RebeccaGrant/Award10.0K
Shareholders
93.1%
Institutional
(125)
2.1%
Insiderⓘ
(5)
13.0%
5%+ Owners
(3)
-
Unattributed (incl. retail)ⓘ
Institutional93.1%
Insider2.1%
5%+ Beneficial13.0%
Sources: 13F, Form 4, 13D/13GO/S: 32.4M · as of 3 Nov 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Key Metrics
Market Cap$1.36B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership93.15%

based on 32.36M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateSep 11, 2025
Shares Outstanding32.36M
Authorized Shares
Float24.22M
52-Week Range
$13.36$50.16
$42.01(78th percentile)
Volume
Average Daily Volume397.65K
480.31K today vs 397.65K avg(+21%)

30d Avg

397.65K

60d Avg

400.00K

90d Avg

360.19K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...